Evidence map›Paper›PMID 22209870›Full record

ReviewFrontiers in neuroendocrinology2012

Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration.

Rory D Spence, Rhonda R Voskuhl

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroendocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03000127 (A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis), which is not on this map. Cited by 129 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 1 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03000127 phase2withdrawnnot on this mapstarted 2018, after this paper: background citation

A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis

TypeinterventionalSponsorUniversity of California, Los AngelesRan2018 to 2024Enrolled0ConditionsMultiple SclerosisArmsAndroGel 1 % Topical Gel, Placebos
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 1 synthesis or guideline pooled it, 251 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. The Effects of Neuroactive Steroids on Myelin in Health and Disease.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rory D SpenceUniversity of California, Los Angeles, Department of Neurology, UCLA Multiple Sclerosis Program, 635 Charles E Young Drive South, Neuroscience Research Building 1, Room 479, Los Angeles, CA 90095, United States. rory.spence@ucla.edu
Rhonda R Voskuhl
University of California, Los Angeles · US

Funding

A Combination Trial of Copaxone Plus Estriol in RRMSR01NS051591 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2007 to 2013
$3.9M
Neuroprotective and Neurogenic Actions of E2 and SERMsR01NS050730 · NINDS · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BRANN, DARRELL W, VADLAMUDI, RATNA K · 2005 to 2014
$3.2M
Training in Molecular, Cellular &Integrative PhysiologyT32GM065823 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIDBALL, JAMES G · 2003 to 2017
$2.1M
Treatment of Multiple Sclerosis with Sex HormonesK24NS062117 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2008 to 2012
$722k
Sex differences in the CNS during diseaseR21NS071210 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2010 to 2011
$420k
NIGMS NIH HHS T32 GM065823NINDS NIH HHS K24NS052117NINDS NIH HHS K24 NS062117NINDS NIH HHS NS050730NINDS NIH HHS R01 NS051591NINDS NIH HHS R21 NS071210
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a disease characterized by inflammation and demyelination. Currently, the cause of MS is unknown. Experimental autoimmune encephalomyelitis (EAE) is the most common mouse model of MS. Treatments with the sex hormones, estrogens and androgens, are capable of offering disease protection during EAE and are currently being used in clinical trials of MS. Beyond endogenous estrogens and androgens, treatments with selective estrogen receptor modulators (SERMs) for estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) are also capable of providing disease protection. This protection includes, but is not limited to, prevention of clinical disease, reduction of CNS inflammation, protection against demyelination, and protection against axonal loss. In EAE, current efforts are focused on using conditional cell specific knockouts of sex hormone receptors to identify the in vivo targets of these estrogens and androgens as well as downstream molecules responsible for disease protection.

Indexed as

AnimalsCentral Nervous System DiseasesDihydrotestosteroneDisease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalEstradiolEstriolEstrogen Receptor alphaEstrogen Receptor betaEstrogensFemaleHumansInflammationMaleMiceMultiple SclerosisDihydrotestosteroneEstradiolEstriolEstrogen Receptor alphaEstrogen Receptor betaEstrogensNeuroprotective AgentsSelective Estrogen Receptor ModulatorsTestosterone

Identifiers

PMID22209870
PMCPMC3616506
OpenAlexW2024695613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.